- Home
- SPRO vs ALGS Comparison
SPRO vs ALGS Comparison
Compare SPRO & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- ALGS
- Stock Information
- Founded
- SPRO 2013
- ALGS 2018
- Country
- SPRO United States
- ALGS United States
- Employees
- SPRO N/A
- ALGS N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- ALGS Biotechnology: Pharmaceutical Preparations
- Sector
- SPRO Health Care
- ALGS Health Care
- Exchange
- SPRO Nasdaq
- ALGS Nasdaq
- Market Cap
- SPRO 45.7M
- ALGS 38.8M
- IPO Year
- SPRO 2017
- ALGS 2020
- Fundamental
- Price
- SPRO $0.69
- ALGS $7.14
- Analyst Decision
- SPRO Buy
- ALGS Strong Buy
- Analyst Count
- SPRO 4
- ALGS 1
- Target Price
- SPRO $5.00
- ALGS $70.00
- AVG Volume (30 Days)
- SPRO 121.5K
- ALGS 140.5K
- Earning Date
- SPRO 03-27-2025
- ALGS 03-10-2025
- Dividend Yield
- SPRO N/A
- ALGS N/A
- EPS Growth
- SPRO N/A
- ALGS N/A
- EPS
- SPRO N/A
- ALGS N/A
- Revenue
- SPRO $47,977,000.00
- ALGS $3,945,000.00
- Revenue This Year
- SPRO N/A
- ALGS $580.86
- Revenue Next Year
- SPRO N/A
- ALGS N/A
- P/E Ratio
- SPRO N/A
- ALGS N/A
- Revenue Growth
- SPRO N/A
- ALGS N/A
- 52 Week Low
- SPRO $0.68
- ALGS $6.76
- 52 Week High
- SPRO $1.81
- ALGS $46.80
- Technical
- Relative Strength Index (RSI)
- SPRO 35.60
- ALGS 24.28
- Support Level
- SPRO $0.75
- ALGS $10.45
- Resistance Level
- SPRO $0.80
- ALGS $9.76
- Average True Range (ATR)
- SPRO 0.05
- ALGS 1.11
- MACD
- SPRO -0.01
- ALGS 0.15
- Stochastic Oscillator
- SPRO 5.83
- ALGS 2.13
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.